Gaps & Progress Toward Achieving a Precision Medicine Model in TBI










Michael McCrea, PhD, ABPP

Professor and Vice Chair

Co-Director, Center for Neurotrauma Research (CNTR)

Department of Neurosurgery

Medical College of Wisconsin

Clement Zablocki VA Medical Center

Modern Precision Medicine

Understanding the Influence of Genomics, Proteomics, Environment, Behavior, and Life Factors on Personal Health

Multidimensional Prediction: Recovery, RTT, Outcome

Precision Medicine & Disease



AIM: Targeted, Personalized Treatment

In Pursuit of Precision Neurotrauma

Where Do We Stand?

(Non) Precision Medicine in Neurotrauma

Uzma Samadani, MD, PhD, FAANS; Samuel R. Daly | Features
AANS Neurosurgeon: Volume 25, Number 3, 2016

Gaps in Precision Medicine for TBI

STRATIFICATION

Characterization, Classification, Phenotyping

THERAPEUTICS

Targeted Intervention
(if any treatment at all)

MEASUREMENT

Response to Treatment, Functional Outcome

What Factors Influence Recovery, Follow-up, Outcome & Risk

Classical TBI Classification

Glasgow Coma Scale

EYE OPENING			VERBAL RESPONSE			MOTOR RESPONSE		
								
Spontaneous	>	4	Orientated	>	5	Obey commands	>	6
To sound	>	3	Confused	>	4	Localising	>	5
To pressure	>	2	Words	>	3	Normal flexion	>	4
None	>	1	Sounds	>	2	Abnormal flexion	>	3
			None	>	1	Extension	>	2
						None	>	1

GLASGOW COMA SCALE SCORE

Mild	Moderate	Severe
13-15	9-12	3-8

Crude Approach to a Complex Condition

TBI Diagnostics & Stratification: "Blunt Precision"





A Critical, But Incomplete Distinction

Not All TBI Created Equal



EDH



Contusion/Hematoma



DAI



SDH



SAH/IVH



Diffuse Swelling

Lack of Precision-Targeted Therapeutics

Adapted from G. Manley, with permission

Precision Medicine Approach to Neurotrauma

GCS



Signs/Sx's

Imaging

Clinical Data

Proteome

Genome

From G. Manley, with permission

Multi-dimensional Enrichment & Prediction

Modern "BIG SCIENCE" in TBI



TRACK-TBI
Transforming Research and Clinical Knowledge in Traumatic Brain Injury
International Traumatic Brain Injury Research Initiative

TBI Endpoints Development
A Collaborative Effort for Advancing Diagnosis and Treatment of TBI

NCAA•DOD Grand Alliance CARE Consortium
A Public-Private Partnership to Advance the Science of Concussion in Sports & Military

TRACK-TBI Precision Medicine

Pathomechanistic Classification of Traumatic Brain Injury:
The Bridge to Targeted Therapies

MTEC
Medical Technology Enterprise Consortium

Solicitation Number: MTEC 18-03-DTTBI
"Drug Treatment for Traumatic Brain Injury (DTTBI)"

TRACK-TBI NET:

An innovative Phase 2 TBI adaptive clinical trials network

Informing the Science of Brain Injury in all Populations at Risk

Advanced Diagnostics in TBI







From Blunt to Precision

Leveraging Technological Advances

White Matter Integrity (DTI/DKI)



Decreased mean diffusivity & increased axial kurtosis at 24 hour injury time point

Functional Connectivity (rs-fMRI)





Cerebral Blood Flow (ASL)



Susceptibility (QSM)



Quantifying Effects of Injury & Recovery using Advanced Imaging

MRI & TBI: Not So "Uncomplicated"

ORIGINAL ARTICLE

Magnetic Resonance Imaging Improves 3-Month Outcome Prediction in Mild Traumatic Brain Injury

Esther L. Yuh, MD, PhD,[1,2] Pratik Mukherjee, MD, PhD,[1,2] Hester F. Lingsma, PhD,[3] John K. Yue, BS,[1,4] Adam R. Ferguson, PhD,[1,4] Wayne A. Gordon, PhD,[5] Alex B. Valadka, MD,[6] David M. Schnyer, PhD,[7] David O. Okonkwo, MD, PhD,[8] Andrew I. R. Maas, MD, PhD,[9] Geoffrey T. Manley, MD, PhD,[1,4] and the TRACK-TBI Investigators

Objective: To determine the clinical relevance, if any, of traumatic intracranial findings on early head computed tomography (CT) and brain magnetic resonance imaging (MRI) to 3-month outcome in mild traumatic brain injury (MTBI).
Methods: One hundred thirty-five MTBI patients evaluated for acute head injury in emergency departments of 3 LEVEL I trauma centers were enrolled prospectively. In addition to admission head CT, early brain MRI was performed 12 ± 3.9 days after injury. Univariate and multivariate logistic regression were used to assess for demographic, clinical, socioeconomic, CT, and MRI features that were predictive of Extended Glasgow Outcome Scale (GOS-E) at 3 months postinjury.
Results: Twenty-seven percent of MTBI patients with normal admission head CT had abnormal early brain MRI. CT evidence of subarachnoid hemorrhage was associated with a multivariate odds ratio of 3.5 ($p = 0.01$) for poorer 3-month outcome, after adjusting for demographic, clinical, and socioeconomic factors. One or more brain contusions on MRI, and ≥4 foci of hemorrhagic axonal injury on MRI, were each independently associated with poorer 3-month outcome, with multivariate odds ratios of 4.5 ($p = 0.01$) and 3.2 ($p = 0.03$), respectively, after adjusting for head CT findings and demographic, clinical, and socioeconomic factors.
Interpretation: In this prospective multicenter observational study, the clinical relevance of abnormal findings on early brain imaging after MTBI is demonstrated. The addition of early CT and MRI markers to a prognostic model based on previously known demographic, clinical, and socioeconomic predictors resulted in a >2-fold increase in the explained variance in 3-month GOS-E.

ANN NEUROL 2013;73:224–235



FIGURE 1: Incidence of computed tomography (CT) versus magnetic resonance imaging (MRI) traumatic brain injury common data element (CDE) abnormalities in 135 study participants. For MRI evidence of contusion and MRI evidence of hemorrhagic axonal injury, progressively darker shades of red indicate larger numbers of lesions (*gray legend*). Study participants with CT evidence of brain contusion had, in most cases, evidence of 1 or 2 hemorrhagic contusions, with no CT demonstrating >3 convincing brain contusions. CT showed evidence of hemorrhagic axonal injury in 3 of 135 study participants, all with 1 to 3 foci of injury. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]

Implications for Predicted Recovery & Outcome

Acute White-Matter Abnormalities in SRC: A DTI Study from the NCAA-DoD CARE Consortium

S. Mustafi, J. Harezlak, K.M. Koch, A.S. Nencka, T.B. Meier, J.D. West, C.C. Giza, J.P. DiFiori, K.M. Guskiewicz, J.P.Mihalik, S.M. LaConte, S.M. Duma, S.P. Broglio, A.J. Saykin, M.McCrea, T.W. McAllister, and Y.C Wu

J Neurotrauma. 2018 Nov 15;35(22):2653-2664.

ACUTE DIFFUSION MRI (24-48 hrs PI)

Concussed vs. Contact Control

Concussed vs. Non-Contact Control



Corrected $p < 0.05$, **Location**: Anterior and posterior corona radiata and corpus callosum

Widespread elevations in mean diffusivity relative to controls

Longitudinal White Matter Abnormalities in SRC: A Diffusion MRI Study of the NCAA-DOD CARE Consortium

Y.C. Wu, J. Harezlak, N.M.H. Elsaid, Z. Lin, Q., Wen, S.M. Mustafi, L.D. Riggen, K.M. Koch, A.S. Nencka, T.B. Meier, A.R. Mayer, Y. Wang, C.C. Giza, J.P. DiFiori, K.M., Guskiewicz, J.P. Mihalik, S.M. LaConte, S.M. Duma, S.P. Broglio, A.J. Saykin, M. McCrea, T.W. McAllister





Burden of acute MD abnormality associated with recovery time

Diagnostic & Prognostic Biomarkers



From: Zetterberg, Smith & Blennow.
Nat Rev Neurol. 2013 Apr; 9(4): 201–210

Objective Biomarkers of Injury & Recovery

Clinical Utility of Biomarkers

Measurement of the Glial Fibrillary Acidic Protein and Its Breakdown Products GFAP-BDP Biomarker for the Detection of Traumatic Brain Injury Compared to Computed Tomography and Magnetic Resonance Imaging

Paul J. McMahon,[1] David M. Panczykowski,[1] John K. Yue,[2] Ava M. Puccio,[1] Tomoo Inoue,[2] Marco D. Sorani,[2] Hester F. Lingsma,[4] Andrew I.R. Maas,[5] Alex B. Valadka,[6] Esther L. Yuh,[3] Pratik Mukherjee,[3] Geoffrey T. Manley,[2] and David O. Okonkwo[1] and TRACK-TBI investigators including: Scott S. Casey,[2] Maxwell Cheong,[3] Shelly R. Cooper,[2] Kristen Dams-O'Connor,[7] Wayne A. Gordon,[7] Allison J. Hricik,[1] Kerri Lawless,[1] David Menon,[8] David M. Schnyer,[9] and Mary J. Vassar[2]

Abstract

Glial fibrillary acidic protein and its breakdown products (GFAP-BDP) are brain-specific proteins released into serum as part of the pathophysiological response after traumatic brain injury (TBI). We performed a multi-center trial to validate and characterize the use of GFAP-BDP levels in the diagnosis of intracranial injury in a broad population of patients with a positive clinical screen for head injury. This multi-center, prospective, cohort study included patients 16–93 years of age presenting to three level 1 trauma centers with suspected TBI (loss of consciousness, post-trauma amnesia, and so on). Serum GFAP-BDP levels were drawn within 24 h and analyzed, in a blinded fashion, using sandwich enzyme-linked immunosorbent assay. The ability of GFAP-BDP to predict intracranial injury on admission computed tomography (CT) as well as delayed magnetic resonance imaging was analyzed by multiple regression and assessed by the area under the receiver operating characteristic curve (AUC). Utility of GFAP-BDP to predict injury and reduce unnecessary CT scans was assessed utilizing decision curve analysis. A total of 215 patients were included, of which 83% suffered mild TBI, 4% moderate, and 12% severe; mean age was 42.1 ± 18 years. Evidence of intracranial injury was present in 51% of the sample (median Rotterdam Score, 2; interquartile range, 2). GFAP-BDP demonstrated very good predictive ability (AUC = 0.87) and demonstrated significant discrimination of injury severity (odds ratio, 1.45; 95% confidence interval, 1.29–1.64). Use of GFAP-BDP yielded a net benefit above clinical screening alone and a net reduction in unnecessary scans by 12–30%. Used in conjunction with other clinical information, rapid measurement of GFAP-BDP is useful in establishing or excluding the diagnosis of radiographically apparent intracranial injury throughout the spectrum of TBI. As an adjunct to current screening practices, GFAP-BDP may help avoid unnecessary CT scans without sacrificing sensitivity (Registry: ClinicalTrials.gov Identifier: NCT01565551).



FIG. 1. Box plots showing median levels of GFAP-BDP measured on admission in two groups of patients. Boxes show interquartile ranges, and I bars represent highest and lowest values. CT, computed tomography;GFAP-BDP, glial fibrillary acidic protein and its breakdown products.



FIG. 3. Receiver-operating-characteristic curves for various cut-off levels of GFAP-BDP in differentiating presence or absence of intracranial injury on CT. Curves for GFAP-BDP alone and after adjustment for known predictors of injury and severity (age, GCS, pupillary reactivity, and ISS). AUC, area under the receiver operating characteristic curve; CI, confidence intreval; CT, computed tomography; GCS, Glasgow Coma Scale; GFAP-BDP, glial fibrillary acidic protein and its breakdown products; ISS, Injury Severity Scale.

Blood Biomarkers After Acute Concussion





Acute Biomarkers Correlate with Recovery Time

FROM BENCH TO BEDSIDE

U.S. Department of Health and Human Services

FDA U.S. FOOD & DRUG ADMINISTRATION

Home | Food | Drugs | Medical Devices | Radiation-Emitting Products | Vaccines, Blood & Biologics | Animal

News & Events

Home > News & Events > Newsroom > Press Announcements

FDA News Release

FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults

New quick testing option to help reduce need for CT scans, radiation exposure for patients

SHARE | TWEET | LINKEDIN | PIN IT | EMAIL | PRINT

For Immediate Release

February 14, 2018

RAPID CLINICAL TRANSLATION

Gaps in Precision Medicine for TBI

STRATIFICATION

Characterization, Classification, Phenotyping

THERAPEUTICS

Targeted Intervention
(if any treatment at all)

MEASUREMENT

Response to Treatment, Functional Outcome

What Factors Influence Recovery, Follow-up, Outcome & Risk

TBI Outcome Measurement

Glasgow Outcome Scale – Extended (GOSE)

1	**Dead**	
2	**Vegetative State (VS)**	Condition of unawareness with only reflex responses but with periods of spontaneous eye opening
3	**Severe Disability – Lower (SD–)**	Dependence on daily support for mental or physical disability or both. If the patient can be left alone for more than 8 hours at home, it is upper level of SD; if not, then it is low level of SD
4	**Severe Disability – Upper (SD+)**	
5	**Moderate Disability – Lower (MD–)**	Patients have some disability such as aphasia, hemiparesis or epilepsy and/or deficits of memory or personality but are able to look after themselves. They are independent at home but dependent outside. If they are able to return to work event with special arrangement it is upper level of MD; if not then it is low level of MD.
6	**Moderate Disability – Upper (MD+)**	
7	**Good Recovery – Lower (GR–)**	Resumption of normal life with the capacity to work even if pre-injury status has not been achieved. Some patients have minor neurological or psychological deficits. If these deficits are not disabling then it is upper level of GR; if disabling, then it is lower level of GR.
8	**Good Recovery – Upper (GR+)**	

Outcome Measurement:
Can We Do Better?

JOURNAL OF NEUROTRAUMA 34:3158–3172 (November 15, 2017)

DOI: 10.1089/neu.2017.5139

Validating Multi-Dimensional Outcome Assessment Using the Traumatic Brain Injury Common Data Elements: An Analysis of the TRACK-TBI Pilot Study Sample

Lindsay D. Nelson,[1] Jana Ranson,[2] Adam R. Ferguson,[3] Joseph Giacino,[4] David O. Okonkwo,[5] Alex B. Valadka,[6] Geoffrey T. Manley,[7] Michael A. McCrea,[1] and the TRACK-TBI Investigators

Abstract

The Glasgow Outcome Scale-Extended (GOSE) is often the primary outcome measure in clinical trials for traumatic brain injury (TBI). Although the GOSE's capture of global functional outcome has several strengths, concerns have been raised about its limited ability to identify mild disability and failure to capture the full scope of problems patients exhibit after TBI. This analysis examined the convergence of disability ratings across a multi-dimensional set of outcome domains in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot Study. The study collected measures recommended by the TBI Common Data Elements (CDE) Workgroup. Patients presenting to three emergency departments with a TBI of any severity enrolled in TRACK-TBI prospectively after injury; outcome measures were collected at 3 and 6 months post-injury. Analyses examined frequency of impairment and overlap between impairment status across the CDE outcome domains of Global Level of Functioning (GOSE), Neuropsychological (cognitive) Impairment, Psychological Status, TBI Symptoms, and Quality of Life. GOSE score correlated in the expected direction with other outcomes (mean [*M*] Spearman's rho = 0.21 and 0.49 with neurocognitive and self-report outcomes, respectively). The subsample in the Upper Good Recovery (GOSE 8) category appeared quite healthy across most other outcomes, although 19.0% had impaired executive functioning (Trail Making Test Part B). A significant minority of participants in the Lower Good Recovery subgroup (GOSE 7) met criteria for impairment across numerous other outcome measures. The findings highlight the multi-dimensional nature of TBI recovery and the limitations of applying only a single outcome measure.

TRACK-TBI
Transforming Research and Clinical Knowledge in Traumatic Brain Injury
International Traumatic Brain Injury Research Initiative

TBI Endpoints Development Initiative
A collaborative for advancing diagnosis and treatment of TBI

MEDICAL COLLEGE OF WISCONSIN
NEUROSURGERY

Center for Neurotrauma Research
Medical College of Wisconsin

6 Month CDE Performance in Good Outcomes
(GOSE 7 & 8)



Good vs. Not So Good Outcome after TBI

Nelson et al, 2017

Good vs. Not So Good Outcome

6 Month Symptom Reporting in Good Outcomes (GOSE 7 & 8)



Nelson et al, 2017

PRECISION NEUROTRAUMA

DETECTION

CHARACTERIZATION



QUANTIFICATION

TOWARD ENRICHMENT, STRATIFICATION AND PREDICTION TO GUIDE PERSONALIZED TREATMENT

IMPROVING OUTCOME AND REDUCING DISABILITY AFTER TBI

Center for Neurotrauma Research

Medical College of Wisconsin

TEAM SCIENCE

MEDICAL COLLEGE OF WISCONSIN

NEUROSURGERY